



PAV-MPL-204-T

Seat No. _____

M. Pharm. (Sem. II) Examination

August / September - 2020

**MPL-204-T : Clinical Research and
Pharmacovigilance**

Time : 3 Hours]

[Total Marks : 75

Instruction : Figure to the right indicates full marks for the respective question.

1 Answer the following : **10×2=20**

- (1) Give the composition of IRB.
- (2) Explain : Pharmacovigilance.
- (3) Write the function of CRO in drug discovery.
- (4) Define Pharmacoeconomics.
- (5) What is Cohort study?
- (6) What is double blind randomized clinical trial?
- (7) What is the difference between ADR and ADE?
- (8) Explain Phase zero clinical trial.
- (9) What is TDM?
- (10) Explain : active surveillance.

2 Answer the following : (Any Two) **2×10=20**

- (1) Explain the core principles and advantages of ICH/GCP guidelines. Explain the role of IRB.
- (2) Explain the principle of ICMR guideline for human participant and explain in detail the inform consent process.
- (3) Explain the types and factors affecting ADR. Describe role of pharmacist in the management of ADR.

3 Answer the following : (Any **Seven**)

7×5=35

- (1) Explain the schedule Y for conducting clinical trial in detail.
- (2) Write a note on contract research organization and its management in drug discovery.
- (3) Describe the concept of safety pharmacology with reference to drug discovery process.
- (4) Explain the roles and responsibility of investigator and sponsor in detail.
- (5) Explain the terms randomized control trial and non-randomized control studies with examples.
- (6) Explain the flow of drug development process. Discuss the phase-III of the same in detail.
- (7) Write a note on Inform consent process.
- (8) Write a short note on Investigator Brochure.
- (9) Explain the evaluation of medication safety.
